Dana Macher leads the Commercialization & Regulatory Practice.
She advises clients on integrated market access strategies, product commercialization plans, and public and private payer engagement strategies. With more than 20 years in the life sciences industry, she successfully launched several oncology products. Dana has extensive knowledge of hospital inpatient and outpatient settings as well as physician office reimbursement systems by effectively positioning novel drugs with payers. She is deeply involved with Avalere’s policy team assessing the impact of payment reform, especially in oncology.
Prior to joining Avalere, Dana was a senior consultant at DK Pierce & Associates, supporting clients in all aspects of coverage, coding, and payment strategies. She led all marketing research efforts, including advisory boards, qualitative interviews, and quick turnaround surveys with payers, KOLs, and practice administrators. Prior, Dana worked for Chiron Therapeutics, a Bay-area biotechnology company where she launched a novel chemotherapeutic agent and provided strategic direction to oncology business units, highlighted by the orchestration of a significant inpatient DRG payment increase with the Centers for Medicare and Medicaid Services.
Dana earned a BS in chemical engineering from Mississippi State University and an MBA from Dartmouth’s Amos Tuck School of Business.